Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Targeting immunoproteasome-dependent β-catenin degradation as a therapeutic strategy in Relapsed/Refractory acute lymphoblastic leukemia

Jodi Forward, Kadriye Nehir Cosgun, Tianhao Yin, Esma Fera, Deepa Bhojwani, David Teachey, Markus Müschen

Blood (2025) 146 (Supplement 1): 5092.

https://doi.org/10.1182/blood-2025-5092

Published: 2025

Journal Articles

Molecular subtypes and BH3 mimetic synergy with anti-leukemia agents in T-cell acute lymphoblastic leukemia

Satoshi Yoshimura, Yizhen Li, Xu Yang, Christian Meyer, Guoqing Du, Yu-Chih Hsiao, Zhenhua Li, Wenjian Yang, Courtney Andersen, Caner Saygin, Seth Karol, Kathrin Bernt, Jiyang Yu, Wendy Stock, David Teachey, Marina Konopleva, Jun J. Yang

Blood (2025) 146 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2025-5081

Published: 2025

Journal Articles

Outcomes in children with NCI standard-risk b-acute lymphoblastic leukemia treated with intensified post-induction therapy: Results from Children's Oncology Group studies AALL0932 and AALL1131

Blood (2025) 146 (Supplement 1): 757.

https://doi.org/10.1182/blood-2025-757

Published: 2025

Journal Articles

Factors associated with central nervous system relapse after b-acute lymphoblastic leukemia: A Children's oncology group report

Blood (2025) 146 (Supplement 1): 762.

https://doi.org/10.1182/blood-2025-762

Published: 2025

Journal Articles

Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium

Blood (2025) 146 (Supplement 1): 761.

https://doi.org/10.1182/blood-2025-761

Published: 2025

Journal Articles

Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731

Blood (2025) 146 (Supplement 1): 758.

https://doi.org/10.1182/blood-2025-758

Published: 2025

Journal Articles

Targeting β-catenin nuclear export and protein degradation in high-risk acute lymphoblastic leukemia

Jodi Forward, Kadriye Nehir Cosgun, Esma Fera, Deepa Bhojwani, David Teachey, Markus Müschen

Blood (2025) 146 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2025-3371

Published: 2025

Journal Articles

Immunophenotypic identification of ETP-like T-ALL using CD1a, CD165 and CD184.

Monica Singh, David Westerman, Stuart Winter, Kimberly Dunsmore, David Teachey, Rawan Shraim, Petri Polonen, Charles Mullighan, Brent Wood

Blood (2025) 146 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2025-3369

Published: 2025

Journal Articles

Inadequate social support and household material hardship among children with pediatric acute lymphoblastic leukemia: A report from the Children's oncology group Trial AALL1731

Blood (2025) 146 (Supplement 1): 132.

https://doi.org/10.1182/blood-2025-132

Published: 2025

Journal Articles

National landscape of real-world pediatric blinatumomab care delivery in the United States: A report from the Children's Oncology Group

Blood (2025) 146 (Supplement 1): 1077.

https://doi.org/10.1182/blood-2025-1077

Published: 2025

Journal Articles

Feasibility of collecting social determinants of health data in the frontline pediatric acute lymphoblastic leukemia (ALL) trial AALL1731: A report from the Children's oncology group

Blood (2025) 146 (Supplement 1): 2742.

https://doi.org/10.1182/blood-2025-2742

Published: 2025

Journal Articles

Tallforest: Multi-omic classifier for T-lineage acute lymphoblastic leukemia

Petri Polonen, Yiping Fan, Shaohua Lei, Qingsong Gao, Yiming Wu, Ti-Cheng Chang, Haley Newman, Lahari Uppuluri, Niroshan Nadarajah, Torsten Haferlach, Marketa Zaliova, Jan Trka, Lu Wang, Hiroto Inaba, Stanley Pounds, Gang Wu, David Teachey, Charles Mullighan

Blood (2025) 146 (Supplement 1): 336.

https://doi.org/10.1182/blood-2025-336

Published: 2025

Journal Articles

HEM-ismart: An international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children

Blood (2025) 146 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2025-1582

Published: 2025

Journal Articles

Immunoglobulin variable gene diversity reflects distinct metabolic/signaling states and impacts measurable residual disease monitoring and clinical outcome in B cell acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 333.

https://doi.org/10.1182/blood-2025-333

Published: 2025

Journal Articles

Outcomes in children and adolescents with down syndrome and B-lymphoblastic leukemia: A report from Children's oncology group study AALL1731

Amanda Li, John Kairalla, Cindy Wang, Meenakshi Devidas, Olga Militano, Johann Hitzler, Anne Angiolillo, Michael Burke, Wanda Salzer, Stephen Hunger, Naomi Winick, David Teachey, Elizabeth Raetz, Mignon Loh, Sumit Gupta, Rachel Rau, Karen Rabin

Blood (2025) 146 (Supplement 1): 547.

https://doi.org/10.1182/blood-2025-547

Published: 2025

Journal Articles

Chemotherapy selects for myeloid subclones in multiple subtypes of B-cell acute lymphoblastic leukemia

Fatemeh Alikarami, Rushabh Mehta, Changya Chen, Lisa Brodersen, David Teachey, Kai Tan, Kathrin Bernt

Blood (2025) 146 (Supplement 1): 35.

https://doi.org/10.1182/blood-2025-35

Published: 2025

Journal Articles

Development of Proteolytic Targeting Chimeras to Target Lck in T-Cell Acute Lymphoblastic Leukemia

Jianzhong Hu, Jamie Jarusiewicz, Jaeki Min, Lei Yang, Divyabharathi Chepyala, Marisa Actis, Lauren Rowland, Guoqing Du, Brandon Smart, Dylan Maxwell, Boer Xie, Satoshi Yoshimura, Junmin Peng, David Teachey, Zoran Rankovic, Jun J. Yang

Blood (2021) 138 (Supplement 1): 867.

https://doi.org/10.1182/blood-2021-147024

Published: 2021

Journal Articles

Treatment Resistance in ETP-ALL Is Associated with Progenitor-like Arrest State

Changya Chen, Jason Xu, Tiffaney Vincent, Chia-hui Chen, Elizabeth Li, Yusha Sun, Jackie Peng, Rawan Shraim, Anusha Thadi, Sydney D'Amaddio, David Teachey, Kai Tan

Blood (2021) 138 (Supplement 1): 618.

https://doi.org/10.1182/blood-2021-153291

Published: 2021

Journal Articles

Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells

David Teachey, MD, Cecilia Sheen, Alix Eden Seif, MD, MPH, Valerie I. Brown, MD, PhD, Stephan A. Grupp, MD, PhD

Blood (2008) 112 (11): 2927.

https://doi.org/10.1182/blood.V112.11.2927.2927

Published: 2008

Journal Articles

IL-7 and Thymic Stromal Lymphopoietin (TSLP) Stimulate Proliferation of All Cells and Reverse mTOR Inhibitor-Induced Growth Inhibition, Suggesting a Role for IL-7Rα Signaling in All.

Valerie I. Brown, MD, PhD, David Teachey, MD, Junjie Fang, MD, Stephan A. Grupp, MD, PhD

Blood (2004) 104 (11): 1893.

https://doi.org/10.1182/blood.V104.11.1893.1893

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Targeting immunoproteasome-dependent β-catenin degradation as a therapeutic strategy in Relapsed/Refractory acute lymphoblastic leukemia

Molecular subtypes and BH3 mimetic synergy with anti-leukemia agents in T-cell acute lymphoblastic leukemia

Outcomes in children with NCI standard-risk b-acute lymphoblastic leukemia treated with intensified post-induction therapy: Results from Children's Oncology Group studies AALL0932 and AALL1131

Factors associated with central nervous system relapse after b-acute lymphoblastic leukemia: A Children's oncology group report

Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium

Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731

Targeting β-catenin nuclear export and protein degradation in high-risk acute lymphoblastic leukemia

Immunophenotypic identification of ETP-like T-ALL using CD1a, CD165 and CD184.

Inadequate social support and household material hardship among children with pediatric acute lymphoblastic leukemia: A report from the Children's oncology group Trial AALL1731

National landscape of real-world pediatric blinatumomab care delivery in the United States: A report from the Children's Oncology Group

Feasibility of collecting social determinants of health data in the frontline pediatric acute lymphoblastic leukemia (ALL) trial AALL1731: A report from the Children's oncology group

Tallforest: Multi-omic classifier for T-lineage acute lymphoblastic leukemia

HEM-ismart: An international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children

Immunoglobulin variable gene diversity reflects distinct metabolic/signaling states and impacts measurable residual disease monitoring and clinical outcome in B cell acute lymphoblastic leukemia

Outcomes in children and adolescents with down syndrome and B-lymphoblastic leukemia: A report from Children's oncology group study AALL1731

Chemotherapy selects for myeloid subclones in multiple subtypes of B-cell acute lymphoblastic leukemia

Development of Proteolytic Targeting Chimeras to Target Lck in T-Cell Acute Lymphoblastic Leukemia

Treatment Resistance in ETP-ALL Is Associated with Progenitor-like Arrest State

Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells

IL-7 and Thymic Stromal Lymphopoietin (TSLP) Stimulate Proliferation of All Cells and Reverse mTOR Inhibitor-Induced Growth Inhibition, Suggesting a Role for IL-7Rα Signaling in All.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only